PKC 412 FLT3 inhibitor therapy in AML: results of a phase II trial.

R. Stone,J. D. de ANGELO,I. Galinsky,E. Estey,V. Klimek,W. Grandin,D. Lebwohl,A. Yap,P. Cohen,E. Fox,D. Neuberg,Jennifer Hayes Clark,D. Gilliland,J. Griffin
Annals of Hematology
Abstract:
What problem does this paper attempt to address?